Online inquiry

IVTScrip™ mRNA-Anti-DLL4&VEGFA, ABT-165(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1244MR)

This product GTTS-WQ1244MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets DLL4&VEGFA gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_019074.4; NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 54567; 7422
UniProt ID Q9NR61; P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-DLL4&VEGFA, ABT-165(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ1244MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9566MR IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JNJ-61186372
GTTS-WQ8889MR IVTScrip™ mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IFN-alpha-REC
GTTS-WQ3745MR IVTScrip™ mRNA-Anti-TFPI, BAY-1093884(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BAY-1093884
GTTS-WQ8155MR IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HL036337
GTTS-WQ15571MR IVTScrip™ mRNA-Anti-AXL, UNII-FFX71LCS5T(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA UNII-FFX71LCS5T
GTTS-WQ3723MR IVTScrip™ mRNA-Anti-MSLN, BAY 94-9343(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BAY 94-9343
GTTS-WQ13242MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PF-05335810
GTTS-WQ5513MR IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CDP4940
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW